| [February 15, 2012] |
 |
Exelixis Announces Closing of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. --(Business Wire)--
Exelixis, Inc. (Nasdaq: EXEL) today announced the completion of its
underwritten public offering of 12,650,000 shares of its common stock,
including 1,650,000 shares sold pursuant to the full exercise of an
option previously granted to the underwriters to purchase additional
shares. All of the shares were offered by Exelixis. Exelixis anticipates
that its aggregate net proceeds from the offering will be approximately
$65.0 million after deducting the underwriting discount and estimated
offering expenses payable by Exelixis.
Goldman, Sachs & Co. acted as sole book running manager, and Cowen and
Company, LLC acted as co-manager of the offering.
The securities described above were offered by Exelixis pursuant to a
shelf registration statement previously filed with the Securities and
Exchange Commissio (SEC (News - Alert)), which the SEC declared effective on May 8,
2009, and a registration statement previously filed with the SEC, which
became effective on February 9, 2012. A final prospectus supplement
related to the offering has been filed with the SEC and is available on
the SEC's website located at http://www.sec.gov.
Copies of the final prospectus supplement relating to the offering and
accompanying prospectus forming a part of the effective registration
statements may be obtained from Goldman, Sachs & Co. (200 West Street,
New York, New York 10282, Attn: Prospectus Department, Phone (News - Alert):
1-866-471-2526, Fax: 212-902-9316, Email: prospectus-ny@ny.email.gs.com)
or from Cowen and Company, LLC (c/o Broadridge Financial Services., 1155
Long Island Avenue, Edgewood, NY,11717, Attn: Prospectus Department,
Phone: 631-274-2806, Fax: 631-254-7140).
This announcement does not constitute an offer to sell or a solicitation
of an offer to buy, nor shall there be any sale of these securities in
any state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Exelixis
Exelixis, Inc. is a biotechnology company committed to developing small
molecule therapeutics for the treatment of cancer.
[ Back To TMCnet.com's Homepage ]
|
TMCnet LOGIN
Webinars
